Advertisement

Topics

FDA Approves Alnylam’s RNAi Therapeutic Onpattro for Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

16:29 EDT 10 Aug 2018 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO is the first and only FDA-approved treatment …

Original Article: FDA Approves Alnylam’s RNAi Therapeutic Onpattro for Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Alnylam’s RNAi Therapeutic Onpattro for Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...